Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma
NCT04842318Phase 4Unknown
- Sponsor
- Ruijin Hospital
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in follicular lymphoma (FL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04842318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842318.